17 June 2008
Ann Transplant 2008; 13(2): 5-11 :: ID: 858100
Liver fibrosis is the final common pathway of most chronic liver diseases of various etiologies.The development of fibrosis determines the management policy as well as the prognosis. In recent years it became clear that the fibrotic process is reversible. Therefore early detection of liver fibrosis is critical. At present, liver biopsy is considered the gold standard for the detection of fibrosis. Nevertheless liver biopsy is an invasive procedure limiting both its acceptance by patients, and their compliance for repeated procedures. More over it is a questionable gold standard due to significant sample error and intra and inter observer variability. These limitations have led to the development of noninvasive techniques for assessing the presence and the degree of liver fibrosis, such as biomarkers and transient elastography. The accuracy of these methods as compared to liver biopsy, as well as their use and limitations are reviewed in the article.
Keywords: biomarkers, FibroTest, Liver biopsy, Liver Diseases, liver fibrosis, Fibroscan
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review articleNormothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588